Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The discovery of long acting beta2-adrenoreceptor agonists.
Brown AD, Bunnage ME, Glossop PA, James K, Jones R, Lane CA, Lewthwaite RA, Mantell S, Perros-Huguet C, Price DA, Trevethick M, Webster R. Brown AD, et al. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4012-5. doi: 10.1016/j.bmcl.2007.04.081. Epub 2007 Apr 29. Bioorg Med Chem Lett. 2007. PMID: 17498952
Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.
Glossop PA, Lane CA, Price DA, Bunnage ME, Lewthwaite RA, James K, Brown AD, Yeadon M, Perros-Huguet C, Trevethick MA, Clarke NP, Webster R, Jones RM, Burrows JL, Feeder N, Taylor SC, Spence FJ. Glossop PA, et al. Among authors: perros huguet c. J Med Chem. 2010 Sep 23;53(18):6640-52. doi: 10.1021/jm1005989. J Med Chem. 2010. PMID: 20804199
Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease.
Glossop PA, Watson CA, Price DA, Bunnage ME, Middleton DS, Wood A, James K, Roberts D, Strang RS, Yeadon M, Perros-Huguet C, Clarke NP, Trevethick MA, Machin I, Stuart EF, Evans SM, Harrison AC, Fairman DA, Agoram B, Burrows JL, Feeder N, Fulton CK, Dillon BR, Entwistle DA, Spence FJ. Glossop PA, et al. Among authors: perros huguet c. J Med Chem. 2011 Oct 13;54(19):6888-904. doi: 10.1021/jm200884j. Epub 2011 Sep 20. J Med Chem. 2011. PMID: 21870878 Clinical Trial.
Targeting fatty acid amide hydrolase as a therapeutic strategy for antitussive therapy.
Wortley MA, Adcock JJ, Dubuis ED, Maher SA, Bonvini SJ, Delescluse I, Kinloch R, McMurray G, Perros-Huguet C, Papakosta M, Birrell MA, Belvisi MG. Wortley MA, et al. Among authors: perros huguet c. Eur Respir J. 2017 Sep 20;50(3):1700782. doi: 10.1183/13993003.00782-2017. Print 2017 Sep. Eur Respir J. 2017. PMID: 28931663 Free article.
Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects.
Singh D, Siew L, Christensen J, Plumb J, Clarke GW, Greenaway S, Perros-Huguet C, Clarke N, Kilty I, Tan L. Singh D, et al. Among authors: perros huguet c. Eur J Clin Pharmacol. 2015 Oct;71(10):1175-84. doi: 10.1007/s00228-015-1920-1. Epub 2015 Aug 13. Eur J Clin Pharmacol. 2015. PMID: 26265232 Free PMC article. Clinical Trial.
13 results